Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968719 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
A Phase 1 study of Alzheimer Disease, sponsored by Corium.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT02968719 is a Phase 1 study of Alzheimer Disease that has completed, run by Corium. The registered enrollment target is 107 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02968719, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Corium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, Randomized, Open-Label, 3-Way Crossover, Pilot, Pharmacokinetic Study to Evaluate the Steady State Pharmacokinetics of a Once-Weekly Application of Corplex Donepezil Transdermal Delivery System (TDS) Compared to Daily Oral Administration of Aricept in Healthy Adult Subjects
Conditions Studied
Interventions
- DRUG Donepezil TDS Version A
- DRUG Donepezil TDS Version B
- DRUG Aricept
- DRUG Donepezil TDS Version D
- DRUG Donepezil TDS Version E
Study Locations (1)
Arizona
- Celerion - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968719
The ClinicalTrials.gov registry entry for NCT02968719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is Corium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Donepezil TDS Version A is the first listed.
NCT02968719 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02968719 about?
NCT02968719 is a clinical study titled "A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®". A Phase 1, Randomized, Open-Label, 3-Way Crossover, Pilot, Pharmacokinetic Study to Evaluate the Steady State Pharmacokinetics of a Once-Weekly Application of Corplex Donepezil Transdermal Delivery System (TDS) Compared to Daily Oral Administration of Aricept in Healthy Adult Subjects
What is the current status of trial NCT02968719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2016-11. Estimated completion is 2017-07-11.
What conditions does trial NCT02968719 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT02968719?
The interventions under investigation include: Donepezil TDS Version A (DRUG), Donepezil TDS Version B (DRUG), Aricept (DRUG), Donepezil TDS Version D (DRUG), Donepezil TDS Version E (DRUG).
Who is sponsoring clinical trial NCT02968719?
This trial is sponsored by Corium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968719 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.